Operating Segments

12 Months Ended

Dec. 31, 2023

Operating Segments

Operating Segments

Note 11. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended
	December 31,
	2023		2022
Revenues
Specialized BioTherapeutics	$	395,124	$	31,929
Public Health Solutions		444,235		916,982
Total	$	839,359	$	948,911
Income (loss) from Operations
Specialized BioTherapeutics	$	(2,812,303)	$	(7,614,988)
Public Health Solutions		(36,531)		26,612
Corporate		(4,849,106)		(6,650,528)
Total	$	(7,697,940)	$	(14,238,904)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	3,932	$	10,087
Public Health Solutions		655		1,681
Corporate		1,967		12,794
Total	$	6,554	$	24,562
Other (Expense) Income, Net
Specialized BioTherapeutics	$	25,267	$	102,320
Corporate		(235,860)		(816,690)
Total	$	(210,593)	$	(714,370)
Share-Based Compensation
Specialized BioTherapeutics	$	145,683	$	138,075
Public Health Solutions		4,782		4,804
Corporate		219,717		190,510
Total	$	370,182	$	333,389

	As of December 31,
	2023		2022
Identifiable Assets
Specialized BioTherapeutics	$	272,099	$	103,742
Public Health Solutions		3,976		121,290
Corporate		9,521,251		14,054,685
Total	$	9,797,326	$	14,279,717